General Proximity de-stealths with funding for next-gen 'undruggable' targets

Californian biotech General Proximity announced its emergence from stealth on Friday, unveiling its proprietary OmniTAC platform designed to pioneer the next generation of induced proximity medicines.

The company has raised $16 million to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.

"We believe proximity medicines are the future of small-molecule drug discovery and have the potential to lower global disease burden more than any other current therapeutic modality," said Armand Cognetta III, founder and chief executive of General Proximity. "Biological proximity - the nearness or interaction of two or more (macro)molecules - is a master regulator of biology. By achieving precise control of proximity through our OmniTAC platform, we are able to modulate 'undruggable' targets more effectively than other approaches. Control of proximity equals control of biology," he noted.